Background: Medication-related interferences with measurements of catecholamines and their metabolites represent important causes of false-positive results during diagnosis of phaeochromocytomas and paragangliomas (PPGLs). Such interferences are less troublesome with measurements by liquid chromatography with tandem mass-spectrometry (LC-MS/MS) than by other methods, but can still present problems for some drugs. Levodopa, the precursor for dopamine used in the treatment of Parkinson’s disease, represents one potentially interfering medication. Methods: Plasma and urine samples, obtained from 20 Parkinsonian patients receiving levodopa, were analysed for concentrations of catecholamines and their O-methylated metabolites by LC-MS/MS. Results were compared with those from a group of 120 age-matched subjects and 18 patients with PPGLs. Results: Plasma and urinary free and deconjugated (freeþconjugated) methoxytyramine, as well as urinary dopamine, showed 22- to 148-fold higher (P<0.0001) concentrations in patients receiving levodopa than in the reference group. In contrast, plasma normetanephrine, urinary noradrenaline and urinary free and deconjugated normetanephrine concentrations were unaffected. Plasma free metanephrine, urinary adrenaline and urinary free and deconjugated metanephrine all showed higher (P<0.05) concentrations in Parkinsonian patients than the reference group, but this was only a problem for adrenaline. Similar to normetanephrine, plasma and urinary metanephrine remained below the 97.5 percentiles of the reference group in almost all Parkinsonian patients. Conclusions: These data establish that although levodopa treatment confounds identification of PPGLs that produce dopamine, the therapy is not a problem for use of LC-MS/MS measurements of plasma and urinary normetanephrine and metanephrine to diagnose more commonly encountered PPGLs that produce noradrenaline or adrenaline.

Over the past 60 years, a large number of selective neurotoxins were discovered and developed, making it possible to animal-model a broad range of human neuropsychiatric and neurodevelopmental disorders. In this paper, we highlight those neurotoxins that are most commonly used as neuroteratologic agents, to either produce lifelong destruction of neurons of a particular phenotype, or a group of neurons linked by a specific class of transporter proteins (i.e., dopamine transporter) or body of receptors for a specific neurotransmitter (i.e., NMDA class of glutamate receptors). Actions of a range of neurotoxins are described: 6-hydroxydopamine (6-OHDA), 6-hydroxydopa, DSP-4, MPTP, methamphetamine, IgG-saporin, domoate, NMDA receptor antagonists, and valproate. Their neuroteratologic features are outlined, as well as those of nerve growth factor, epidermal growth factor, and that of stress. The value of each of these neurotoxins in animal modeling of human neurologic, neurodegenerative, and neuropsychiatric disorders is discussed in terms of the respective value as well as limitations of the derived animal model. Neuroteratologic agents have proven to be of immense importance for understanding how associated neural systems in human neural disorders may be better targeted by new therapeutic agents.

Le trouble de l’odorat est un symptôme fréquent bien connu de la Maladie de Parkinson (MP). Il apparaît plusieurs années avant la possibilité d’un diagnostic de la maladie et son étude est ainsi d’intérêt particulier pour aider au développement d’outils de dépistage précoces et la sélection de candidats pouvant participer à des essais cliniques visant le développement de traitements potentiellement curateurs. Pour ce faire, il est important de différencier un trouble de l’odorat associé à la MP d’autres troubles de l’odorat non reliés à une maladie neurodégénérative (trouble de l’odorat non-parkinsonien : TONP), tels que des troubles de l’odorat liés à une infection virale, à un traumatisme craniocérébral ou des troubles sinu-nasaux. Le système olfactif est plus complexe qu’il ne le semble et est intimement lié au système trigéminal, un système moins bien connu, qui permet, entre autres, la perception de sensations de fraicheur, chaleur et picotement des odeurs. L’interaction entre les systèmes olfactif et trigéminal est complexe et peu connue. La sensibilité trigéminale est typiquement réduite dans le cas d’un système olfactif altéré dans les TONP, mais il n’est pas bien compris comment les deux systèmes interagissent ensemble dans le cas d’un trouble de l’odorat associé à la MP. L’objectif principal de cette thèse visait donc la caractérisation du trouble de l’odorat associé à la MP lorsque spécifiquement comparé à des patients atteints de TONP. Par conséquent, cette thèse avait aussi pour objectif d’apporter une meilleure compréhension de l’interaction entre les systèmes olfactif et trigéminal dans le cas d’un système olfactif fonctionnel et d’un système olfactif altéré dans la MP et d’autres TONP. Nous avons donc d’abord évalué la sensibilité olfactive et trigéminale, sur le plan comportemental (étude 1). Cette première étude a permis d’identifier un patron de réponse spécifique dans la MP avec un système olfactif altéré et un système trigéminal intact,en comparaison à des contrôles, en contraste à une sensibilité trigéminale réduite dans les TONP. Dans le même ordre d’idée, nous avons ensuite évalué la perception des dimensions trigéminales et olfactives de différentes odeurs (étude 2). Nos résultats suggèrent que la perception de sensations trigéminales est intacte chez les patients avec la MP en contraste à la perception de dimensions olfactives qui est réduite, comparativement à des contrôles. Pour mieux comprendre l’interaction entre le système olfactif et trigéminal dans le cas d’un système olfactif fonctionnel, nous avons ensuite évalué l’impact d’un stimulus olfactif sur la capacité à latéraliser un stimulus trigéminal chez des participants contrôles (étude 3). Cette étude a démontré un effet d’amplification de la réponse trigéminale lors d’une co-stimulation olfactive ipsilatérale suggérant ainsi une interaction au niveau de l’épithélium nasal. Afin de mieux comprendre la réponse trigéminale dans la MP, nous avons évalué la sensibilité trigéminale périphérique et centrale en réponse à un stimulus trigéminal pur via des mesures électrophysiologiques (étude 4). Nous avons ainsi démontré une altération spécifique de la réponse trigéminale dans la MP comparativement à d’autres TONP et à des contrôles. Puisque le bulbe olfactif est l’une des premières régions affectées dans la MP, nous avons ensuite mesuré le volume du bulbe olfactif sur des images IRM (étude 5). Nos résultats ont démontré un volume réduit dans la MP et les TONP comparativement à des contrôles, mais aucune différence entre les patients atteints de la MP et de TONP. Néanmoins, l’utilisation de techniques d’apprentissage profond sur les images IRM du bulbe olfactif a permis de différencier les patients avec la MP des TONP avec une exactitude considérable. Enfin, nous avons étudié la connectivité fonctionnelle au sein du réseau chimiosensoriel (étude 6). Nous avons ainsi identifié des altérations spécifiques de la connectivité et la modularité des réseaux entre des régions de traitement olfactif et trigéminal au repos et lors de la réalisation d’une tâche olfactive et d’une tâche trigéminale chez des patients atteints de la MP en comparaison avec des TONP et des contrôles. En conclusion, la série d’études présentée dans cette thèse contribue à une meilleure compréhension du trouble de l’odorat associé à la MP et propose de potentielles pistes pour le différencier d’autres TONP, notamment par la mesure du système trigéminal. Cette thèse apporte une meilleure compréhension de l’interaction entre le système olfactif et trigéminal dans un système olfactif fonctionnel et de son altération dans les troubles olfactifs associés à la MP ou à d’autres TONP. La caractérisation de ce symptôme non-moteur pourra éventuellement aider au développement d’outils de dépistage précoce de la MP. / Olfactory dysfunction is a highly reliable non-motor symptom of Parkinson’s disease (PD) that appears several years before the possibility of a diagnosis of the disease. Hence, its study is of particular interest to help the development of early diagnosis tools and the selection of ideal candidates to participate in clinical trials that aims to test potential neuroprotective treatments. To do so, it is important to differentiate PD-related olfactory dysfunction from other non-neurodegenerative forms of olfactory dysfunctions that can be related to infections, head trauma or sinonasal disease (non-parkinsonian olfactory dysfunction: NPOD). The olfactory system is more complex than it seems and is intimately connected to the trigeminal system, a less well-known system, that allows, amongst others, the perception of sensation of freshness, warmth, and piquancy of odors. The interaction between the olfactory and trigeminal system is complex and not well understood. Trigeminal sensitivity is typically reduced in cases of an impaired olfactory system related to NPOD; however, this is not clear how both systems interact together in PD-related olfactory dysfunction. The main objective of this thesis was to principally characterize PD-related olfactory dysfunction when specifically compared to patients with NPOD. Consequently, this thesis also aimed to bring a better understanding of the interaction between the olfactory and trigeminal system in a fully functional olfactory system as well as in alterations of the olfactory system associated with PD and other NPOD. We have thus first assessed the olfactory and trigeminal sensitivity using behavioral measures (study 1). This study allowed the identification of a specific response pattern in PD patients with an altered olfactory system and an intact trigeminal system, when compared to controls, in contrast to the reduced trigeminal sensitivity observed in NPOD. We then evaluated the perception of trigeminal and olfactory dimensions of different odors (study 2). Our results suggest that the perception of trigeminal sensations is intact in patients with PD in contrast to the perception of olfactory dimensions which is reduced when compared to control participants. To better understand the interaction between the olfactory and trigeminal systems in a functioning olfactory system, we evaluated the impact of an olfactory stimulus on the capacity to lateralize a trigeminal stimulus in healthy participants (study 3). This study has demonstrated an amplification effect of the olfactory system on the trigeminal system particularly during ipsilateral co-stimulation, suggesting an interaction at the level of the olfactory mucosa. To better understand the trigeminal response in PD patients, we further investigated the peripheral and central trigeminal sensitivity in response to a pure trigeminal stimulus by means of electrophysiological measurements (study 4). We thus demonstrated a specific alteration of the trigeminal response in PD patients when specifically compared to patients with NPOD and healthy control participants. As the olfactory bulb is one of the first regions to be affected in PD, we then measured the olfactory bulb volume on MRI scans (study 5). Our results showed reduced olfactory bulb volume in PD patients as well as in NPOD, when compared to controls, but no difference between PD and NPOD patients. Interestingly, the use of deep learning techniques on MRI scans of the olfactory bulb allowed the discrimination between PD patients and NPOD patients with considerable accuracy. Finally, we investigated the functional connectivity within the chemosensory network (study 6). We identified a specific pattern of functional connectivity and chemosensory network modularity in PD patients at resting-state and while performing an olfactory or a trigeminal task, when specifically compared to patients with NPOD and controls. In conclusion, all taken together, the studies presented in this thesis contributes to a better understanding of the PD-related olfactory dysfunction and suggest potential avenues to differentiate it from NPOD, notably through the measurement of the trigeminal system. This thesis brings further knowledge regarding the interaction between the olfactory and trigeminal systems in a functional olfactory system and its alteration in cases of an impaired olfactory system related to PD or NPOD. The characterization of this non-motor symptom of the disease will eventually help the development of early diagnostic tools for PD.

La dopamine est un neurotransmetteur important dans le fonctionnement des ganglions de la base, région du cerveau impliquée dans la fonction motrice et l’apprentissage. Un dérèglement de la dynamique de la dopamine peut être à l’origine de différentes pathologies neurologiques, telles que la maladie de Parkinson et le trouble de déficit de l’attention avec ou sans hyperactivité (TDAH). La lévodopa, un précurseur de la dopamine, est utilisée pour réduire les symptômes associés à la maladie de Parkinson, sans action directe sur ses causes. La lévodopa est très efficace au début de la maladie, mais la durée de son effet ainsi que son index thérapeutique diminuent avec la progression de la dénervation induite par la maladie. Ces changements compliquent considérablement l’optimisation des régimes posologiques. Le méthylphénidate, quant à lui, est administré pour réduire les symptômes du TDAH et agit entre autres en bloquant la recapture de la dopamine. Bien que les données confirment une certaine implication de la dopamine dans le TDAH, son étiologie exacte demeure inconnue. Peu d’études ont cerné l’effet de la lévodopa sur le système dopaminergique des ganglions de la base et son évolution avec la progression de la maladie. Aussi, bien que le TDAH ait suscité beaucoup d’intérêt, rares sont les études quantitatives de nature mécanistiques sur le sujet. L’approche de modélisation mathématique utilisée dans cette thèse s’inscrit dans un effort global visant l’optimisation de la lévodopa et du méthylphénidate, appuyé par l’élucidation des mécanismes impliqués dans la maladie de Parkinson et dans le TDAH. En adoptant une approche de pharmacologie quantitative des systèmes (QSP), nous avons développé un modèle intégratif du système dopaminergique des ganglions de la base, avec l’objectif d’élucider les mécanismes impliqués, d’évaluer l’impact de la dopamine chez dessujets souffrant de Parkinson ou de TDAH, et recevant ou non un traitement, et enfin de guider objectivement l’exercice d’optimisation des régimes posologiques. À notre connaissance, c’est le premier cadre unificateur de modélisation qui s’adresse à ces deux pathologies. Le modèle développé dans cette thèse est composé de trois sous-modèles : le premier décrit la pharmacocinétique du médicament concerné, soit la lévodopa ou le méthylphénidate ; le deuxième exprime mathématiquement les différents mécanismes impliqués dans la dynamique de la dopamine ; le troisième représente la complexité de la neurotransmission dans les ganglions de la base. Avec des adaptations appropriées, nous avons appliqué ce même modèle au contexte de la maladie de Parkinson et au TDAH, ainsi qu’à leurs thérapies respectives. Pour représenter physiologiquement la maladie de Parkinson, nous avons intégré dans le modèle l’évolution de la perte neuronale ainsi que les différents mécanismes de compensation qui en résultent. La fréquence de tapotement des doigts est utilisée comme mesure clinique de la bradykinésie, définie comme le ralentissement des mouvements chez les patients parkinsoniens. Le modèle développé se base sur les connaissances actuelles de la pathophysiologie et pharmacologie du Parkinson, assurant ainsi sa validité en comparaison à des observations expérimentales et cliniques. Ensuite, à l’aide de ce modèle, les relations non-linéaires entre la concentration plasmatique de lévodopa, la concentration en dopamine dans le cerveau et la réponse à une tâche motrice sont étudiées. Le rétrécissement de l’index thérapeutique de la lévodopa au cours de la progression de la maladie dû à ces non-linéarités est investigué. Enfin, pour assurer l’aspect translationnel de notre approche, nous avons développé une application web à laquelle ce modèle a été intégré. Cette application sert de preuve de concept à un outil facilitant l’optimisation et l’individualisation des régimes posologiques. Pour l’étude du TDAH, nous avons adapté le modèle du système dopaminergique en y intégrant la libération tonique et phasique de la dopamine, cette dernière se produisant durant une tâche d’apprentissage par renforcement. Des individus virtuels ont été créés avec et sans déséquilibre du ratio tonique/phasique de la dopamine. En simulant une tâche de réponse à des stimuli dans un contexte de déséquilibre de la dopamine, le modèle nous a permis d’observer des symptômes similiaires à ceux de patients réels souffrant de TDAH. Finalement, la réponse au méthylphénidate résultant de l’inhibition de la recapture de la dopamine, à travers différents scénarios d’apprentissage a aussi été étudiée. Le développement d’une métrique nous a permis de différencier les répondants des non-répondants, et ainsi de mettre en évidence l’implication possible d’un apprentissage excessif chez les nonrépondants. Une meilleure compréhension de la réponse au méthylphénidate permettrait d’éviter la surmédication chez les non-répondants et d’aider les cliniciens dans leur pratique. Malgré la complexité du système dopaminergique et des traitements associés, cette thèse est un pas en avant dans la compréhension des mécanismes sous-jacents et de leur implication dans la thérapie. Ces avancées ont été réalisées en adoptant une approche de pharmacologie quantitative des systèmes, associée à une modélisation neurocomputationnelle du domaine du génie électrique, et complétée par un aspect de transfert au chevet du patient. Ce n’est qu’en transcendant ainsi les frontières disciplinaires qu’une visée aussi globale et intégrative est possible, afin de faire face aux défis multidimensionnels du système de la santé. / Dopamine is an important neurotransmitter of the basal ganglia, a region of the brain involved in motor function and learning. Disruption of dopamine dynamics can cause various neurological conditions, such as Parkinson’s disease and attention deficit hyperactivity disorder (ADHD). Levodopa, a dopamine precursor, is used to reduce the symptoms associated with Parkinson’s disease, without directly alleviating its causes. Levodopa is very effective in the early stages of the disease, but its effect duration along with its therapeutic index decrease with disease-induced denervation. These modifications further challenge determination of optimal dosing regimens of levodopa. In the case of ADHD, methylphenidate is administered to reduce its symptoms by, among other things, blocking dopamine recapture. Although evidence supports involvement of dopamine in ADHD, its exact etiology remains unknown. Few studies have investigated the effect of levodopa on the basal ganglia dopaminergic system and how it evolves with disease progression. Also, although ADHD has received a lot of interest, few quantitative studies of a mechanistic nature have been conducted on the subject. The mathematical modeling approach used in this thesis is part of an overall effort to optimize levodopa and methylphenidate, supported by the elucidation of the mechanisms involved in Parkinson’s disease and ADHD. Using a quantitative systems pharmacology (QSP) approach, we have developed an integrative model of the basal ganglia dopaminergic system, with the objective of elucidating the mechanisms involved, assessing the impact of dopamine in subjects with Parkinson’s or ADHD, with and without treatment, and objectively guiding the dosing regimens optimization. To the best of our knowledge, this is the first unifying modeling framework that addresses at the same time these two pathologies and their therapies. The model developed in this thesis includes three sub-models: the first one describes the drug pharmacokinetics, either levodopa or methylphenidate; the second one translates mathematically the different mechanisms involved in the dopamine dynamics; the third one is a computational representation of the complexity of neurotransmission in the basal ganglia. With appropriate adaptations, we have applied this same model to the context of Parkinson’s disease and ADHD, as well as to their respective pharmacotherapies. In order to physiologically represent Parkinson’s disease, we have integrated the denervation process in the model as well as the resulting compensation mechanisms. The finger tapping frequency is used as a clinical endpoint of bradykinesia, defined as the slowing of movements. The developed model is based on up-to-date knowledge of the pathophysiology and pharmacology of Parkinson’s disease, thus ensuring its validity in comparison with experimental and clinical observations. Using this model, the non-linear relationships between plasma levodopa concentration, dopamine concentration in the brain and response to a motor task were studied. The narrowing of levodopa therapeutic index during the progression of the disease due to these non-linearities was investigated. Finally, to ensure the translational aspect of our approach, we developed a web application in which this model was integrated. This application serves as a proof of concept for a tool aimed to facilitate the optimization and individualization of dosing regimens. For the study of ADHD, we adapted the developed model by integrating tonic and phasic dopamine release, the latter occurring during a reinforcement learning task. Virtual individuals were created with and without dopamine imbalance in the tonic/phasic ratio. By simulating a stimulus-response task, we observe ADHD-like symptoms among virtual patients with dopamine imbalance. Finally, the response to methylphenidate resulting from dopamine recapture inhibition, through different learning scenarios, was also studied. The development of a metric allowed us to differentiate responders from non-responders, and thus to highlight the possible implication of excessive learning in non-responders. A better understanding of methylphenidate response would help avoid overmedication in non-responders and assist clinicians in their practice. Despite the complexity of the dopaminergic system and its associated therapies, this thesis is a step forward in understanding the underlying mechanisms and their involvement in pharmacotherapy. These advances were achieved by adopting a quantitative systems pharmacology approach, combined with neurocomputational modeling borrowed from the electrical engineering field, and complemented by a translational bedside aspect. It is only by transcending disciplinary boundaries and adopting such an integrative approach that this ultimate goal of having a real impact on the multifaceted health system is possible.

In this thesis, two different architecture designs of a Multi-Layer Perceptron network have been implemented. One architecture being an ordinary MLP, and in the other adding DenseNet inspired skip connections to an MLP architecture. The models were used and evaluated on the classification task, where the goal was to classify if subjects were diagnosed with Parkinson’s disease or not based on vocal features. The models were trained on an openly available dataset for Parkinson’s classification and evaluated on a hold-out set from this dataset and on two datasets recorded in another sound recording environment than the training data. The thesis searched for the answer to two questions; How insensitive models for Parkinson’s classification are to the sound recording environment and how the proposed skip connections in an MLP model could help improve performance and generalization capacity. The thesis results show that the sound environment affects the accuracy. Nevertheless, it concludes that one would be able to overcome this with more time and allow for good accuracy when models are exposed to data from a new sound environment than the training data. As for the question, if the skip connections improve accuracy and generalization, the thesis cannot draw any broad conclusions due to the data that were used. The models had, in general, the best performance with shallow networks, and it is with deeper networks that the skip connections are argued to help improve these attributes. However, when evaluating on the data from a different sound recording environment than the training data, the skip connections had the best performance in two out of three tests. / I denna avhandling har två olika arkitektur designer för ett artificiellt flerskikts neuralt nätverk implementerats. En arkitektur som följer konventionen för ett vanlig MLP nätverk, samt en ny arkitektur som introducerar DenseNet inspirerade genvägs kopplingar i MLP nätverk. Modellerna användes och utvärderades för klassificering, vars mål var att urskilja försökspersoner som friska eller diagnostiserade med Parkinsons sjukdom baserat på röst attribut. Modellerna tränades på ett öppet tillgänglig dataset för Parkinsons klassificering och utvärderades på en delmängd av denna data som inte hade använts för träningen, samt två dataset som kommer från en annan ljudinspelnings miljö än datan för träningen. Avhandlingen sökte efter svaret på två frågor; Hur okänsliga modeller för Parkinsons klassificering är för ljudinspelnings miljön och hur de föreslagna genvägs kopplingarna i en MLP-modell kan bidra till att förbättra prestanda och generalisering kapacitet. Resultaten av avhandlingen visar att ljudmiljön påverkar noggrannheten, men drar slutsatsen att med mer tid skulle man troligen kunna övervinna detta och möjliggöra god noggrannhet i nya ljudmiljöer. När det kommer till om genvägs kopplingarna förbättrar noggrannhet och generalisering, är avhandlingen inte i stånd att dra några breda slutsatser på grund av den data som användes. Modellerna hade generellt bästa prestanda med grunda nätverk, och det är i djupare nätverk som genvägs kopplingarna argumenteras för att förbättra dessa egenskaper. Med det sagt, om man bara kollade på resultaten på datan som är ifrån en annan ljudinspelnings miljö så hade genvägs arkitekturen bättre resultat i två av de tre testerna som utfördes.

Deep brain stimulation (DBS) is a potent symptomatic therapy for Parkinson’s disease, but it is debated whether it causes or prevents neurodegeneration. We used serum neurofilament light chain (NFL) as a reporter for neuronal damage and found no difference between 92 patients with chronic STN-DBS and 57 patients on best medical treatment. Serum NFL transiently increased after DBS surgery whereas the initiation of STN stimulation did not affect NFL levels, suggesting that DBS surgery can be associated with neuronal damage whereas stimulation itself is not.

Είναι γνωστό ότι η άνοια σχετίζεται με την απώλεια μνήμης, έκπτωση γλωσσικών ικανοτήτων, έλλειψη αυτονομίας και απώλεια της προσωπικής ταυτότητας του ασθενούς. Στόχος της παρούσας εργασίας είναι να αναδείξει τη σχέση αμφισημίας- άνοιας και να διερευνηθεί η σκοπιμότητα ύπαρξης ενός μεθοδολογικού εργαλείου για την εκτίμηση και τη διερεύνηση της γλωσσικής έκπτωσης στη άνοια μέσα από την γλωσσική επεξεργασία των λεξικών σχέσεων (μεταφορών –ομωνυμίας- μετωνυμιών) και να παρουσιάζει το προφίλ των ασθενών αυτών. Στην πρώτη ενότητα παρουσιάζω γενικά στοιχεία για την νόσο της άνοιας αλλά και στοιχεία για τους κυριότερους τύπους της νόσου όσον αφορά την γλωσσική συμπεριφορά των ασθενών. Στην ενότητα αυτή αναφέρω επίσης βασικά διαγνωστικά εργαλεία που χρησιμοποιούνται ευρέως για τον προσδιορισμό της νόσου, ενώ αναλυτικότερα στοιχεία για τα εργαλεία που χρησιμοποιούνται και τις δομές που εξετάζουν παρατίθενται στο παράρτημα. Κλείνοντας την ενότητα καταλήγω στα οφέλη και την αναγκαιότητα ύπαρξης πρώιμης διάγνωσης. Στην δεύτερη ενότητα αναφέρομαι κυρίως στο νοητικό λεξικό και στην δυσκολία πρόσβασης των ασθενών με πιθανή άνοια σε αυτό. Επιπλέον υπάρχουν στοιχεία για την λεξική κατάκτηση, επιλογή και ανάκτηση των πληροφοριών και φαίνεται η σχέση νοητικού λεξικού – αμφισημίας. Στην τρίτη ενότητα παρουσιάζω το φαινόμενο της αμφισημίας από την θεωρητική άποψη αρχικά της γλωσσολογίας, πως κατακτώνται οι αμφίσημες λέξεις και επεξεργάζονται σε σχέση με την ηλικία και καταλήγω στην νευρική συσχέτιση των λεξικών αμφισημιών με συγκεκριμένες εγκεφαλικές περιοχές. Στο τέλος της παρούσας ενότητας παρουσιάζω ευρήματα/ συμπεράσματα από πλήθος ερευνών που αφορούν την λεξική αμφισημία με διαφορετικές μεθόδους για κάθε τύπο άνοιας. Στην τελευταία ενότητα παρουσιάζω τις βασικές υποθέσεις μου πως η χρήση των λεξικών σχέσεων θα μπορεί να αποτελέσει διαγνωστικό εργαλείο στην άνοια. Επίσης παρουσιάζω την κατασκευή και τα αποτελέσματα της πειραματικής διαδικασίας ανάμεσα σε τέσσερα διαφορετικά υποκείμενα (πασχόντων –υγειών) διαφορετικής παθολογίας και σοβαρότητας. Ακολουθεί τέλος το παράρτημα με στοιχεία που αφορούν την διαφοροδιάγνωση της νόσου βάσει αλγορίθμων με τα γνωστικά ελλείμματα όπως παρουσιάζονται από τους φροντιστές των ασθενών αλλά και παθολογικών συμπτωμάτων που παρουσιάζουν, ενώ σε πίνακα υπάρχουν τα γλωσσικά στοιχεία που βοηθούν επίσης στην διαφοροδιάγνωση των κυριότερων τύπων άνοιας και τα αποτελέσματα της πειραματικής διαδικασίας. / It is well known that dementia is associated with memory loss, impaired language skills, lack of autonomy and loss of patients’ independence. The aim of this paper is to highlight the connection between ambiguity and dementia, and to investigate the feasibility of a methodological tool to assess and investigate the linguistic deduction in dementia through the linguistic processing of lexical relations (metaphor-homonymy-metonymy) and present the profile of such patients. In the first section I present general information as well as the linguistic features of the main types of dementia. In this section there is also a report on the diagnostic tools which are widely used to identify the disease. More detailed information about the use of these diagnostic tools is listed in the Annex. At the end of this section there is evidence about the benefits and the importance of early diagnosis. The second section is mainly referred to the mental lexicon and the difficulty patients with probable dementia face in accessing it. Furthermore there is evidence for lexical acquisition, selection and retrieval of information which shows the mental lexicon – ambiguity connection. In the third section I present the phenomenon of ambiguity, starting from the theoretical linguistic view; how the ambiguous words are conquered and processed in relation to age and lead to neural correlation of lexical ambiguity with specific brain regions. At the end of this section I present findings / conclusions of several researches, using different methods, on the lexical ambiguity on each type of dementia. The last section presents my basic assumptions concerning how the use of lexical relations can be a diagnostic tool in dementia. Furthermore, I present the construction and the results of the experimental process between four different subjects (patient-healthy) with different pathology and severity of the disease. Finally, at the annex, I present data on the differential diagnosis of the disease based on algorithms with cognitive deficits reported by caregivers of patients as well as pathology features. Also there is a board with differential linguistic elements which help distinguish the main types of dementia, along with the experimental material used and the results of the procedure.

Parkinson’s disease (PD) is a neurodegenerative disorder that is characterised by a reduction of dopamine concentration in the striatum due to degeneration of dopaminergic neurons in the substantia nigra. Currently, first line treatment of PD includes the use of dopamine precursors, dopamine agonists and inhibitors of enzymatic degradation of dopamine, in an effort to restore dopamine levels and/or its effects. However, all these therapeutic strategies are only symptomatic and unfortunately do not slow, stop or reverse the progression of PD. From the discovery of adenosine A2A receptor-dopamine D2 receptor heteromers and the antagonistic interaction between these receptors, the basis of a new therapeutic approach towards the treatment of PD emerged. Adenosine A2A receptor antagonists have been shown to decrease the motor symptoms associated with PD, and are also potentially neuroprotective. The possibility thus exists that the administration of an adenosine A2A antagonist may prevent further neurodegeneration. Furthermore, the antagonism of adenosine A1 receptors has the potential of treating cognitive deficits such as those associated with Alzheimer's disease and PD. Therefore, dual antagonism of adenosine A1 and A2A receptors would be of great benefit since this would potentially treat both the motor as well as the cognitive impairment associated with PD. The affinities (Ki-values between 0.6 mM and 38 mM) of a series of 1,4-dihydropyridine derivatives were previously illustrated for the adenosine A1, A2A and A3 receptor subtypes by Van Rhee and co-workers (1996). These results prompted this pilot study, which aimed to investigate the potential of the structurally related 3,4-dihydropyrimidin-2(1H)-ones (dihydropyrimidones) and 2-amino-1,4-dihydropyrimidines as adenosine A1 and A2A antagonists. In this pilot study, a series of 3,4-dihydropyrimidones and 2-amino-1,4-dihydropyrimidines were synthesised and evaluated as adenosine A1 and A2A antagonists. Since several adenosine A2A antagonists also exhibit MAO inhibitory activity, the MAO-inhibitory activity of selected derivatives was also assessed. A modified Biginelli one pot synthesis was used for the preparation of both series of compounds under solvent free conditions. A mixture of a β- diketone, aldehyde and urea/guanidine hydrochloride was heated for an appropriate time to afford the desired compounds in good yields. MAO-B inhibition studies comprised of a fluorometric assay where kynuramine was used as substrate. A radioligand binding protocol described in literature was employed to investigate the binding of the compounds to the adenosine A2A and A1 receptors. The displacement of N-[3H]ethyladenosin-5’-uronamide ([3H]NECA) from rat striatal membranes and 1,3-[3H]-dipropyl-8-cyclopentylxanthine ([3H]DPCPX) from rat whole brain membranes, was used in the determination of A2A and A1 affinity, respectively. The results showed that both 3,4-dihydropyrimidones and 2-amino-1,4-dihydropyrimidines had weak adenosine A2A affinity, with the p-fluorophenyl substituted dihydropyrimidone derivative (1h) in series 1, exhibiting the highest affinity for the adenosine A2A receptor (28.7 μM), followed by the p-chlorophenyl dihydropyrimidine derivative (2c) in series 2 (38.59 μM). Both series showed more promising adenosine A1 receptor affinity in the low micromolar range. The p-bromophenyl substituted derivatives in both series showed the best affinity for the adenosine A1 receptor with Ki-values of 7.39 μM (1b) and 7.9 μM (2b). The pmethoxyphenyl dihydropyrimidone (1d) and p-methylpneyl dihydropyrimidine (2e) derivatives also exhibited reasonable affinity for the adenosine A1 receptor with Ki-values of 8.53 μM and 9.67 μM, respectively. Neither the 3,4-dihydropyrimidones nor the 2-amino-1,4- dihydropyrimidines showed MAO-B inhibitory activity. Comparison of the adenosine A2A affinity of the most potent derivative (1h, Ki = 28.7 μM) from this study with that of the previously synthesised dihydropyridine derivatives (Van Rhee et al., 1996, most potent compound had a Ki = 2.74 mM) reveals that an approximate 100- fold increase in binding affinity for A2A receptors occurred. However, KW6002, a known A2A antagonist, that has already reached clinical trials, has a Ki-value of 7.49 nM. The same trend was observed for adenosine A1 affinity, where the most potent compound (1b) of this study exhibited a Ki-value of 7.39 μM compared to 2.75 mM determined for the most potent dihydropyridine derivatives (Van Rhee et al., 1996). N6-cyclopentyladenosine (CPA), a known adenosine A1 agonist that was used as a reference compound, however had a Kivalue of 10.4 nM. The increase in both adenosine A1 and A2A affinity can most likely be ascribed to the increase in nitrogens in the heterocyclic ring (from a dihydropyridine to a dihydropyrimidine) since similar results were obtained by Gillespie and co-workers in 2009 for a series of pyridine and pyrimidine derivatives. In their case it was found that increasing the number of nitrogens in the heterocyclic ring (from one to two nitrogen atoms for the pyridine and pyrimidine derivatives respectively) increased affinity for the adenosine A2A and adenosine A1 receptor subtypes, while three nitrogen atoms in the ring (triazine derivatives) were associated with decreased affinity. It thus appears that two nitrogen atoms in the ring (pyrimidine) are required for optimum adenosine A1 and A2A receptor affinity. The poor adenosine A2A affinity exhibited by the compounds of this study can probably be attributed to the absence of an aromatic heterocyclic ring. The amino acid, Phe-168 plays a very important role in the binding site of the A2A receptor, where it forms aromatic - - stacking interactions with the heterocyclic aromatic ring systems of known agonists and antagonists. Since the dihydropyrimidine ring in both series of this pilot study was not aromatic, the formation of aromatic - -stacking interactions with Phe-168 is unlikely. In conclusion, the 3,4-dihydropyrimidone and 2-amino-1,4-dihydropyrimidine scaffolds can be used as a lead for the design of novel adenosine A1 and A2A antagonists, although further structural modifications are required before a clinically viable candidate will be available as potential treatment of PD. / MSc (Pharmaceutical Chemistry), North-West University, Potchefstroom Campus, 2014

A challenge for the clinical management of Parkinson's disease (PD) is the large within- and between-patient variability in symptom profiles as well as the emergence of motor complications which represent a significant source of disability in patients. This thesis deals with the development and evaluation of methods and systems for supporting the management of PD by using repeated measures, consisting of subjective assessments of symptoms and objective assessments of motor function through fine motor tests (spirography and tapping), collected by means of a telemetry touch screen device. One aim of the thesis was to develop methods for objective quantification and analysis of the severity of motor impairments being represented in spiral drawings and tapping results. This was accomplished by first quantifying the digitized movement data with time series analysis and then using them in data-driven modelling for automating the process of assessment of symptom severity. The objective measures were then analysed with respect to subjective assessments of motor conditions. Another aim was to develop a method for providing comparable information content as clinical rating scales by combining subjective and objective measures into composite scores, using time series analysis and data driven methods. The scores represent six symptom dimensions and an overall test score for reflecting the global health condition of the patient. In addition, the thesis presents the development of a web-based system for providing a visual representation of symptoms over time allowing clinicians to remotely monitor the symptom profiles of their patients. The quality of the methods was assessed by reporting different metrics of validity, reliability and sensitivity to treatment interventions and natural PD progression over time. Results from two studies demonstrated that the methods developed for the fine motor tests had good metrics indicating that they are appropriate to quantitatively and objectively assess the severity of motor impairments of PD patients. The fine motor tests captured different symptoms; spiral drawing impairment and tapping accuracy related to dyskinesias (involuntary movements) whereas tapping speed related to bradykinesia (slowness of movements). A longitudinal data analysis indicated that the six symptom dimensions and the overall test score contained important elements of information of the clinical scales and can be used to measure effects of PD treatment interventions and disease progression. A usability evaluation of the web-based system showed that the information presented in the system was comparable to qualitative clinical observations and the system was recognized as a tool that will assist in the management of patients.

No description available.